PINOVA THERAPEUTICS
Live / Applied — Revived — awaiting further action (as of 17 Oct 2025)
What this means for you
Not registered yet, but its 19 Nov 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97135396
- Mark type
- Stylized text
- Filed
- 19 Nov 2021
- Published for opposition
- 18 Jul 2023
- Attorney of record
- Spencer Wolff Esquire
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for the treatment of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy side effects, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty
- Class 042 — Scientific and technological services: scientific research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty; pharmaceutical research and development into treatments of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty
- Class 044 — Medical, beauty and agricultural services: medical and healthcare information services namely providing medical and healthcare information in the fields of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty
Owner
- Pocket Naloxone Corp., Bethesda, MD, US
- Pocket Naloxone Corp., Bethesda, MD, US
Prosecution history
- 17 Oct 2025 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 17 Oct 2025 — NOTICE OF REVIVAL - E-MAILED
- 17 Oct 2025 — PETITION TO REVIVE-GRANTED
- 17 Oct 2025 — TEAS PETITION TO REVIVE RECEIVED
- 13 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 13 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 20 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Feb 2025 — SOU EXTENSION 3 GRANTED
- 19 Feb 2025 — SOU EXTENSION 3 FILED
- 19 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 21 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Aug 2024 — SOU EXTENSION 2 GRANTED
- 21 Aug 2024 — SOU EXTENSION 2 FILED
- 21 Aug 2024 — SOU TEAS EXTENSION RECEIVED
- 05 Mar 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED